NaphCare Addresses Connecticut Lawmakers Debating Opioid Treatment for State Inmates

BIRMINGHAM, AL — NaphCare, Inc., an independent partner to correctional facilities nationwide for innovative healthcare management and technology solutions, addressed the Connecticut General Assembly’s Public Health Committee during their scheduled meeting on Friday, March 16th. The committee heard testimony on a proposed bill that aims to establish a treatment program in each of the state’s 15 correctional facilities for inmates suffering from health issues associated with opioid dependence.

In his comments, Bradford T. McLane, J.D., NaphCare’s Chief of Operations for Administration, expressed support for expanding Medication Assisted Treatment in corrections. Connecticut ranks in the top 10 states in the country for dependence on illicit drugs for adults aged 18 to 25.

SB Bill 172 instructs the Connecticut Department of Corrections to develop a Medication Assisted Treatment (MAT) program by  January 1, 2019, and then to roll the program out over four years so that 100% of all inmates will have access by 2023. Such an MAT program uses medications in combination with behavioral therapies to safely manage an inmate through the process of opioid withdrawal, administered by medical professionals on-site at each jail or prison.

NaphCare has substantial and growing experience in caring for opioid-addicted patients. Mr. McLane informed the committee that NaphCare is currently in the early stages of operating a pilot, in-jail MAT program in Middlesex County, New Jersey, whereby a protocol is in place that greatly reduces the risks and the suffering that patients endure as they withdraw from opioids in the correctional setting.

“Importantly, all inmates who receive MAT medications need to also receive counseling and behavioral therapies,” adds Mr. McLane. “It is also of critical importance that jail-based healthcare staff include discharge planners who can work with community providers to connect patients to care upon discharge. After all, the real test of whether treatment is effective will come when the patient is released from jail or prison and experiences that first temptation to return to abusing opioids.”

About NaphCare

NaphCare exists to improve the lives of our patients by administering competent, caring healthcare solutions in an environment of respect and professionalism. We want to lead the correctional healthcare industry forward through the continuous development of our proactive, preventative approach to care delivery. To discover more about how NaphCare provides cost-efficient solutions, visit us at

Release Date: 03/20/2018